Protocol Ledger

NCT07165951 · Phase III · RECRUITING

Clinical Trial Comparing TQB2868 Injection Combined With Anlotinib Hydrochloride Capsules With Placebo Combined With Chemotherapy as First-line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)

Interventional Phase III clinical trial protocol NCT07165951 sponsored by Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-12-02 Enrollment: 566 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07165951
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)566 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07165951
Protocol FieldVerified Registry Value
NCT IdentifierNCT07165951
Consolidated Lead SponsorShanghai Chia Tai Tianqing Pharmaceutical Technology Development Co
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment566 participants (ESTIMATED)
Registered Start Date2025-12-02
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI